Biopharma | April 16, 2026
Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Research by NITI Aayog and All India Institute of Medical Sciences has shown that at least 30% of trauma deaths are linked to delays in emergency response
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
The new unit is expected to serve thousands of patients annually, helping address a critical gap in dialysis access
The new outpatient-focused clinic is designed to address voice, airway and swallowing disorders through advanced diagnostics
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Through the partnership, she plans to share her experience—from consultation through recovery—across her social media platforms
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
